Chemistry:Indisulam
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
N1-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide | |
| Other names
E7070
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C14H12ClN3O4S2 | |
| Molar mass | 385.84 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Indisulam is a chloroindolyl sulfonamide cell cycle inhibitor that exhibits antitumor activity in vitro and in an animal model.[1][2][3] This compound affects cell cycle progression in human tumor cells and is being studied for the treatment of cancers such as melanomas and blood-borne cancers such as leukemia.[4]
References
- ↑ "Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells". Invest New Drugs 19 (3): 219–27. 2001. doi:10.1023/A:1010608317361. PMID 11561678.
- ↑ "E7070, a Novel Sulphonamide Agent With Potent Antitumour Activity in Vitro and in Vivo". European Journal of Cancer 37 (17): 2275–82. November 2001. doi:10.1016/s0959-8049(01)00275-1. PMID 11677118.
- ↑ E. Raymond; W.W. ten Bokkel Huinink; J. Taïeb; J.H. Beijnen; S. Faivre; J. WandersM. Ravic; P. Fumoleau; J.P. Armand et al. (2002-08-15). "Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer". Journal of Clinical Oncology 20 (16): 3508–21. doi:10.1200/JCO.2002.09.030. PMID 12177112.
- ↑ Rita Assi; Hagop M. Kantarjian; Jorge E. Cortes; Tapan Kadia; Naveen Pemmaraju; Elias J. Jabbour; Nitin Jain; Naval Daver et al. (2001). "Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)". Blood 130 (supplement 1). https://ashpublications.org/blood/article/130/Supplement%201/1380/116008/Final-Results-of-Phase-2-Open-Label-Study-of-E7070.
 |  |
